Medicinal Cannabis Access in South Australia: A Regulatory Overview

Roughly 3.7 million Australians now live in South Australia, and over the past few years the volume of questions I get about medicinal cannabis access from that state , from readers, from clinicians in regional towns, from a pharmacist I met on a café ride near the Heysen Trail , has grown noticeably. The questions are usually the same: is it legal? Who can prescribe it? What schedule is it? The short version is: yes, it's legal under specific conditions, but the pathway matters enormously, and SA law adds a layer on top of the federal framework.

That layering is what most people miss.

The federal floor: scheduling under the Poisons Standard

Australia's medicinal cannabis regime sits on a federal base. The Therapeutic Goods Administration (TGA) controls both the scheduling of cannabis-derived substances under the Poisons Standard (the SUSMP) and the listing or registration of products on the Australian Register of Therapeutic Goods (ARTG).

Under the current Poisons Standard, the relevant entries break broadly as follows:

• Cannabidiol (CBD) in low-concentration preparations meeting specific criteria sits in Schedule 4 (prescription only) , meaning a registered medical practitioner can prescribe it through normal channels.
• Most other cannabinoid preparations containing tetrahydrocannabinol (THC) above very low thresholds are classified as Schedule 8 controlled drugs. That classification brings significantly more regulatory weight: additional record-keeping, prescription format requirements, and; the part most relevant to SA, a requirement for state and territory authority.

One registered product (a specific CBD oral solution) was down-scheduled to Schedule 3 pharmacy-only in 2021, allowing pharmacist supply without a prescription under defined conditions. That remains the exception, not the rule.

Where South Australia adds its own layer

Schedule 8 status under the federal Poisons Standard doesn't automatically authorise prescribing. States and territories each have their own controlled substances legislation, and for SA that means the Controlled Substances Act 1984 (SA) and associated regulations. A practitioner in Adelaide prescribing a Schedule 8 medicinal cannabis product must comply with both the federal scheduling framework and SA's own controlled substances requirements.

SA Health administers the state-level framework. For Schedule 8 medicinal cannabis, a prescriber generally needs approval from the Chief Pharmacist (or a delegate) via the SA Health Controlled Substances approval process, unless an exemption applies. The specifics, which forms, which exemptions, which clinical governance conditions; are detailed on SA Health's website and do change periodically. I'd always recommend verifying the current position directly with SA Health rather than relying on any secondary source, including this one.

There's also a notification distinction worth knowing. Some prescribers with relevant clinical experience or endorsement may notify rather than seek prior approval for certain patients, but the conditions attaching to that pathway are specific and not universal. If you're a clinician reading this, the SA Health Medicines and Technology unit is your direct point of contact.

Federal prescribing pathways: SAS and Authorised Prescriber

Layered on top of state requirements are the TGA's own access pathways for products not listed on the ARTG. The vast majority of medicinal cannabis products prescribed in Australia, and this is still true in 2024, are not formally registered on the ARTG. They're accessed via:

• The Special Access Scheme (SAS), typically Category B, where a practitioner applies to the TGA for approval to supply a specific unapproved product to a specific patient.
• The Authorised Prescriber (AP) scheme, where a medical practitioner gains TGA endorsement to prescribe a specified product to a class of patients without needing individual SAS approvals each time.

Both pathways require the practitioner to hold relevant SA state authority as well. Neither pathway bypasses the state layer. This is a point of genuine confusion; I've seen people assume a TGA SAS approval is sufficient on its own. It isn't, at least not for Schedule 8 products in SA.

Good Manufacturing Practice (GMP) certification is also relevant to product quality. Importers and manufacturers must meet GMP standards for therapeutic goods, which the TGA audits. From a patient perspective this matters because it underpins consistency and labelling accuracy in what ends up on the shelf.

What patients actually encounter

From a patient's point of view, access in SA typically starts with a GP or specialist. The clinician assesses whether a cannabis-derived product is appropriate for the patient's circumstances, navigates both the TGA approval pathway and the SA Health authority requirement, writes the prescription, and the patient fills it at a pharmacy, usually a pharmacy that has prior arrangements in place to source the relevant product.

The products themselves vary considerably in their cannabinoid profiles. Some are primarily cannabidiol (CBD)-dominant; others contain meaningful proportions of THC; many are formulated as full-spectrum or broad-spectrum extracts that include a range of minor cannabinoids and terpenes. The scientific discussion around how these components interact is ongoing, the concept sometimes called the entourage effect, discussed in our entourage effect glossary entry, reflects some of that complexity, though the research picture is still far from settled.

Route of administration also matters pharmacologically. How a cannabinoid is absorbed, how quickly it reaches systemic circulation, and how it's metabolised differs substantially between inhaled, sublingual, and oral preparations. For those interested in the underlying science, our entries on bioavailability and first-pass metabolism give some useful background on why a capsule and an oil taken at the same nominal dose behave differently in the body.

Driving, workplace, and impairment law

This deserves its own section because it catches people out. SA's Road Traffic Act and associated road rules prohibit driving with a prescribed concentration of THC in oral fluid, blood, or urine; regardless of whether the THC came from a lawfully prescribed product. There is no medicinal use defence for drug-driving charges in SA, mirroring the position in most other Australian jurisdictions.

I'll be honest: I think this is an area where law has lagged behind the access regime in a way that creates genuine tension for patients, particularly those in regional SA who rely on driving. That's not a claim about therapeutic benefit, it's an observation about regulatory coherence. But that's where things currently stand, and patients need to understand it clearly before commencing any THC-containing treatment.

Workplace policies similarly vary. Some SA industries, mining, transport, heavy machinery; carry their own drug testing frameworks that don't distinguish between prescribed and non-prescribed use. Patients and their clinicians are well served by discussing this before prescribing.

Minors and additional safeguards

Prescribing medicinal cannabis to patients under 18 in SA carries additional requirements. The Chief Pharmacist approval process applies, and in practice paediatric cases typically involve specialist input. The TGA also maintains additional oversight considerations for paediatric SAS applications. This is an area where the framework is deliberately conservative, and the approval process reflects that.

Keeping up as the rules change

SA's medicinal cannabis regulatory position has shifted multiple times since the federal framework was established in 2016, and it will shift again. The TGA reviews scheduling entries; SA Health updates its approval processes; the list of ARTG-registered products grows slowly. What was accurate eighteen months ago may not reflect today's requirements.

Trevor (my sourdough starter, for those who haven't met him) is more predictable than regulatory change in this space, he always wants more attention and always forgives neglect eventually. Regulatory frameworks are less forgiving when you assume they've stayed still.

The authoritative sources are SA Health's Medicines and Technology unit and the TGA's own guidance on medicinal cannabis. Both publish current versions of their requirements online. For practitioners, the TGA's Authorised Prescriber and SAS guidance documents are updated regularly and should be the first port of call, not third-party summaries.

Sources

• Medicinal Cannabis: Guidance, Products and Application Forms, Therapeutic Goods Administration (TGA)
• Controlled Substances Information for Health Professionals; SA Health
• The Poisons Standard (SUSMP), Therapeutic Goods Administration (TGA)
• Medicinal Cannabis, Australian Government Department of Health and Aged Care

, Marcus Hale, Regulatory researcher; TGA & access law